In the present study, a screen of adenosine analogs as potential modulators of arylamine-N-acetyltransferase 1 activity identified ATP as an inhibitor within its range of physiological concentrations. Kinetically, ATP was a non-competitive inhibitor with respect to the acetyl acceptor but a competitive inhibitor with respect to the acetyl donor (acetyl-coenzyme A). In silico modelling predicted that ATP bound within the active site cleft arranged with the triphosphate group in close proximity to arginine 127. Since lysine 100 has previously been implicated in the binding of acetyl-coenzyme A to the enzyme, this amino acid was mutated to either an arginine or a glutamine. Both substitutions significantly changed the affinity of ATP for the enzyme, as well as the nature of the interaction to one with a large Hill coefficient (> 3). Under these conditions, ATP was a strong allosteric modulator of arylamine-N-acetyltransferase 1 activity. Western blot analysis identified lysine 100 as a site of post-translational modification by acetylation. The results suggest that acetylation of lysine 100 converts arylamine-N-acetyltransferase 1 into a switch modulated by ATP. This observation provides important understanding of the molecular regulation of NAT1 activity and may reveal possible insight into the endogenous role of the enzyme.
Introduction
The arylamine N-acetyltransferases (NAT's; EC 2.3.1.5) catalyze the acetylation of arylamine and hydrazine compounds [1] . As a family of enzymes, they are conserved across both prokaryotic and eukaryotic species [2] . They are characterized by the presence of a cysteine-histamine-aspartate catalytic triad, structurally similar to the cysteine protease superfamily of proteins [3] . The NAT's transfer an acetyl group from acetyl-coenzyme A (AcCoA) to the substrate via a double displacement or ping-pong bi bi reaction mechanism [4] . Both the catalytic triad and the reaction mechanism uniquely distinguishes the NAT's from other known acetyltransferases.
In humans, there are two closely-related NAT's (NAT1 and NAT2), and both their structure and catalytic functions have been described [5] [6] [7] [8] . The NAT's are genetically polymorphic, which can affect both their enzymatic activity and their stability [9, 10] . The presence of different single nucleotide polymorphisms has been associated with increased risk of cancer, drug-induced liver disease, and type II diabetes [8] . In addition to its role in drug metabolism, NAT1 has been shown to affect cell growth and survival [11] [12] [13] [14] as well as several intracellular metabolic pathways [15] [16] [17] [18] [19] . These biological effects have prompted a number of investigators to propose that the NAT's may be possible targets for drug development [6, 8, 20] .
The activity of many enzymes is regulated by allosteric modulation where an effector molecule binds and either increases or decreases function. Like most enzymes that utilize a double displacement reaction mechanism, the NAT's exhibit substrate and product inhibition. However, there are no known allosteric modulators for either of these enzymes. NAT1 and NAT2 acetylate a range of small molecule arylamines, although their substrate specificities are very different. This difference has been mapped to several amino acids within the active site cleft of each isozyme [21] . The structure of NAT-CoA co-crystals revealed the precise binding domains for AcCoA in the active site [22] , and these findings have been supported by mutagenesis studies. Specific amino acids, primarily in the β2, β3 and α9 domains, interact with the di-phosphate and adenosine moieties of AcCoA to align the acetyl group close to the active site cysteine. This binding arrangement suggests that other molecules that possess an adenosine-phosphate structure may also interact with the NAT's. In the present study, a number of endogenous molecules were screened to determine their effects on NAT1 catalytic activity. From this, it was found that ATP is a strong allosteric modulator of NAT1 activity at physiological concentrations suggesting the enzyme may be affected by changes in ATP concentrations in vivo.
Materials and methods

Materials
ATP, ADP, AMP, cAMP, methioadenosine, ADP-ribose, AcCoA and p-aminobenzoic acid were purchased from Sigma Chemicals, St Louis, Missouri, USA. All other chemicals were of analytical grade.
Cell culture and transfection
HeLa cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 medium supplemented with 5% fetal bovine serum at 37°C in a humidified 5% CO 2 atmosphere.
Cells were seeded at 0.6 × 10 6 cells per well in 6-well plates and allowed to adhere overnight. They were then transiently transfected with 4 µg plasmid DNA (p3XFLAG-CMV-7.1-NAT1-WT, p3XFLAG-CMV-
L or p3XFLAG-CMV-7.1-NAT1-K 99 L) using Lipofectamine 2000 reagent (ThermoFisher Scientific, Carlsbad, CA, USA) as described elsewhere [23] .
Recombinant protein
The NAT1 coding sequences were excised from the mammalian expression vector p3XFLAG-CMV-7.1 and re-cloned into the bacterial expression vector pT7-FLAG-1 (Sigma Chemicals, St Louis, Missouri, USA). BL21-CodonPlus competent bacteria were then transformed with the different pT7-FLAG-1 plasmids and recombinant FLAG-NAT1 proteins purified using anti-FLAG M2 magnetic beads according to the supplier's protocol. Briefly, 200 ml LB was inoculated with 20 ml overnight cultures and grown to an OD of 1.0. The temperature was then reduced to 20°C and cultures treated with 1 mM IPTG and incubated overnight. Bacteria were then pelleted, lysed in 30 ml FLAG lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA and 1% TRITON X-100) and immunoprecipitated with anti-FLAG M2 magnetic beads (Sigma Chemicals, St Louis, Missouri, USA) according to the manufacturer's instructions. FLAG-tagged NAT1 proteins were then eluted from the beads using 3X FLAG peptide (Sigma Chemicals, St Louis, Missouri, USA) as described in the supplier's protocol. Protein purity was checked by SDS-PAGE with Coomassie blue staining and protein concentration was determined by the Bradford protein assay.
NAT1 assay
NAT1 activity was assayed using p-aminobenzoic acid (PABA) as acetyl acceptor and AcCoA as acetyl donor. N-Acetyl-PABA was measured by high performance liquid chromatography [9] . Briefly, 10 ng of recombinant protein was incubated at 37°C for 10 min with PABA, AcCoA with and without ATP (concentrations shown in Section 3). Reactions were terminated by rapidly heating the reaction mixture to 95°C for 3 min. All reactions were performed under linear conditions with respect to substrate and protein. NAT1 activities were normalized to the amount of recombinant protein in each reaction.
Immunoprecipitation and Western blotting
Transfected HeLa cells were washed twice with cold PBS, lysed in 0.8 ml FLAG lysis buffer and immunoprecipitated with anti-FLAG M2 magnetic beads (Sigma Chemicals, St Louis, Missouri, USA) according to the manufacturer's instructions. Beads containing immunoprecipitated FLAG proteins were then boiled in Laemmli buffer. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blocked with 5% BSA in PBS containing 0.1% Tween-20 (PBST) for 1 h. Membranes were then incubated overnight at 4°C with primary antibodies diluted 1:1000 in blocking buffer. Primary antibodies for acetylated-lysine (#9441), SUMO-1 (#493) and ubiquitin (#3936) were from Cell Signalling Technology Inc, Danvers, MA, USA, and methylated-lysine (SAB5200093) was from Sigma Chemicals, St Louis, Missouri, USA. Membranes were then washed with PBST and incubated for 1 h with either peroxidase-conjugated goat anti-rabbit IgG or peroxidase-conjugated goat anti-mouse IgG secondary antibodies (Jackson ImmunoResearch Laboratories Inc. West Grove, Pennsylvania, USA) diluted 1:30,000 in PBST. Membranes were washed with PBST and then immunoblots detected using WESTAR Nova 2.0 chemiluminescent reagent (Cyanagen, Bologna, Italy).
In silico modelling of ATP binding to NAT1
The crystal structure of human NAT1 [22] was downloaded from the Protein Data Bank (pdb code 2PQT). The side chain of Lys100 at the entry of the substrate binding pocket is not present in the structure, due to lack of electron density, but this was added and energy minimised using the sculpt function in the PyMol Molecular Graphics System (version 2.0, Schrödinger, LLC, USA). NAT1 and ATP input files were prepared using AutoDock Tools and ATP blind docked to NAT1 using AutoDock Vina [24] , following the standard rigid body docking protocol outlined in the AutoDock Vina manual. The resultant binding poses were all located in the active site, but represented subtle variants of two distinct binding conformations, with either the phosphates or the adenine group inserted into the binding pocket. The complexes were visualised and analysed using PyMol.
Data analysis
The Michaelis-Menten equation with substrate inhibition was fitted to each data set for substrate concentration versus activity. For experiments to determine ATP inhibition of NAT1, a substrate inhibition equation that included the Hill coefficient was used. All kinetic parameters were estimated by nonlinear least squares regression using GraphPad Prism 6 (GraphPad Software, La Jolla, USA) and convergence was confirmed by initiating the iterative process from at least 3 independent initial estimates. Comparisons were performed using a Student's t-test.
Results
Screen of endogenous molecules as modulators of NAT1 activity
The common substrate for all arylamine N-acetyltransferases is the acetyl donor AcCoA. In the double displacement reaction mechanism, AcCoA occupies the active site first, acetylating the cysteine of the catalytic triad. To identify potential modifiers of AcCoA binding, molecules with a similar adenosine phosphate moiety were tested using recombinant human NAT1 and p-aminobenzoic acid (PABA) as the acetyl acceptor. The compounds included ATP, NAD+, cAMP, ADPribose and methylthioadenosine (MTA), and the structure for each is shown in Fig. 1 . At a concentration of 1 mM, only ATP altered NAT1 activity, inhibiting the enzyme by approximately 50% (Fig. 2A ). This observation was interesting because the intracellular concentration of ATP ranges from 1 to 5 mM, although it can be much higher in diseases such as cancer [25] . In the cytoplasm where NAT1 is primarily located, the ATP concentration is approximately 3 mM [25] .
Next, the effects of GTP and CTP on NAT1 activity were investigated. GTP has a guanine and CTP has a cytosine in the place of the adenine in ATP. Both compounds inhibited NAT1 to the same extent as ATP (Fig. 2B ). This result suggested that the base in ATP was not critical for inhibition. However, the intracellular concentrations of both CTP and GTP are less than 20% of that for ATP [25] . To assess the importance of the phosphate groups, the effects of AMP and ADP were compared to that for ATP (Fig. 2C) . There was an increase in inhibition as the number of phosphate groups increased. Moreover, MTA, which has no phosphates attached to the ribose group, had no effect on NAT1 activity ( Fig. 2A) . Taken together, these results suggest that the effects of ATP on NAT1 primarily involves the triphosphate group.
Concentration-dependent inhibition of NAT1 by ATP
The acetylation of PABA (1 mM) was measured at a fixed concentration of AcCoA (1 mM) and increasing concentrations of ATP (Fig. 3A) . ATP demonstrated a concentration-dependent inhibition of the enzyme with an IC 50 of 1.7 ± 0.1 mM. Because ATP is normally bound to Mg 2+ , which coordinates the triphosphates, inhibition was also measured with 0.5 mM ATP and 2 mM Mg 2+ (Fig. 3B) . There was no effect of the cation on NAT1 activity either in the presence or absence of ATP.
Effect of ATP on NAT1 kinetics
To understand the possible mechanism of NAT1 inhibition by ATP, steady state kinetics were determined with constant AcCoA and variable PABA (Fig. 4A) or constant PABA and variable AcCoA (Fig. 4B) using an ATP concentration of 1 mM. For variable PABA, ATP induced a significant decrease in Vmax from 191 nmol/min/ng protein to 79 nmol/min/ng protein (Table 1) . There was no change in the estimated Km. This is indicative of a non-competitive inhibitor, which is also illustrated by the parallel shift in the curve when the data are graphed as a double reciprocal plot (Fig. 4A, right panel) .
For constant PABA (0.3 mM) and variable AcCoA, ATP showed competitive inhibition. The Km of the reaction was 242 μM and 651 μM in the absence and presence of 1 mM ATP, respectively (Table 2 ). There was no change in the apparent Vmax (81 ± 3 and 73 ± 4 nmol/min/ ng protein, respectively). Competitive inhibition was also illustrated by the double reciprocal plot of the data (Fig. 4B, right panel) .
In silico modelling of ATP binding to NAT1
Blind docking of ATP to NAT1 was performed using AutoDock Vina without a priori knowledge of possible binding site(s). This software employs an algorithm for rapid energy evaluations by pre-calculating atomic affinities using a three-dimensional grid approach. The structure of the NAT1 protein was obtained from its crystal coordinates (2PQT) and is shown in Fig. 5A with the secondary structure in blue and the surface contour in greyscale. The black box frames the mouth of the active site cavity where the catalytic cysteine (Cys 68 ) is located down to the left and the conserved arginine (Arg
127
) is located down to the right. The docking configuration with the lowest free energy was chosen as the optimum binding conformation. In silico modelling predicted that AutoDock also reported an alternative arrangement with ATP bound to the active site in an orientation with the adenine moiety inserted into the cavity. The change in free energy was −7.8-8.0 kcal/mol suggesting that it is less favorable than the orientation shown in Fig. 5 . However, the modelling assumes a single rigid conformation for NAT1, which is unlikely to be the case. Consequently, this binding arrangement cannot be discounted.
Lys 100 regulates ATP binding to NAT1 in vitro
Lys 100 is conserved in all mammalian NAT's. It regulates NAT1 kinetics through its interaction with the 3′-phosphate in AcCoA to stabilize the AcCoA-NAT1 complex [23] . To determine whether Lys 100 influences ATP inhibition of NAT1, the amino acid was substituted with a glutamate, which changes the charge of the side-chain, or with an 
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arginine, which changes the shape of the side-chain but conserves the charge. Then, the acetylation of PABA (0.3 mM) was measured in the presence of 0.5 mM AcCoA and increasing concentrations of ATP (Fig. 6A ). For the wild-type NAT1, the IC 50 for ATP was 1.4 ± 0.2 mM, which is similar to that seen in Fig. 3A . For the Lys
100
Gln mutant, the IC 50 increased to 3.9 ± 0.2 mM. Thus, substitution at the Lys 100 position decreased the potency of ATP as an inhibitor of NAT1. Interestingly, the slope of the curve (Hill coefficient) increased three-fold from 1.1 ± 0.2 to 3.3 ± 0.5. For the Lys 100 Arg mutant, similar kinetics to the Lys
Gln mutant was seen where the IC 50 for ATP was 3.8 ± 0.2 mM and the Hill coefficient was 2.1 ± 0.2.
The larger Hill coefficient seen with the mutant proteins is indicative of a cooperative interaction between ATP and NAT1. The amino acid substitutions modified the effect that ATP has on enzyme activity. For the wild-type enzyme, ATP exhibited a relatively constant inhibitory effect throughout its physiological concentration. NAT1 activity decreased from 80% to 20% of control over an eleven-fold range of ATP concentrations (0.5-5.5 mM). By contrast, when Lys 100 was substituted with either glutamine or arginine, the concentration range for the same decrease in NAT1 activity was 2.5-5.5 mM, or just over two-fold.
Post-translational modification of NAT1 in whole cells
The side-chain of lysine is a site for various post-translational modifications in many proteins [26] . Since Lys 100 substituted NAT1 significantly altered the response to ATP, post-translational modifications of NAT1 were investigated by Western blot analysis. Using ectopically expressed FLAG-tagged wild-type and the Lys 100
Gln substituted NAT1 constructs, HeLa cells were transfected for 24 hr following which cell cytosols were immunoprecipitated with anti-FLAG antibody. The expression of each protein was similar (Fig. 6B, FLAG blot) . There was no evidence for ubiquitination, sumoylation or methylation of either protein. By contrast, a pan anti-acetyl-lysine antibody showed the presence of acetylated FLAG-tagged protein (Fig. 6B, left lane) . This was significantly attenuated when Lys 100 was substituted with a glutamine, suggesting that Lys 100 is post-translationally modified by acetylation. The decrease in acetylated NAT1 was not due to the specific type of modification since replacing Lys 100 with a leucine resulted in the same decrease (Fig. 6C) Gln NAT1 was acetylated to the same extent as the wildtype protein (Fig. 6D) . It is noteworthy that there was still evidence of acetylated protein in the Lys 100 mutants suggesting NAT1 may be modified on other lysines as well. 
Table 2
Kinetic parameters for NAT1 with variable AcCoA concentrations.
Discussion
The arylamine N-acetyltransferases were first identified as a family of enzymes that catalyzed the acetylation of numerous drugs and other xenobiotics. Recently, however, deletion studies in both cell and animal models have indicated that both enzymes (NAT1 and NAT2) have a role in cell metabolism [11] [12] [13] [14] [15] [16] [17] [18] [19] . The activity of the NATs is regulated at a transcriptional and post-transcriptional level [8] , but post-translational modifications have not been reported until now. Moreover, the modifications appear to play an important role in modulating the activity of NAT1 in vivo. NAT1 has been reported to affect the methionine salvage pathway [19] , mitochondrial function [18] and fatty acid synthesis [16] suggesting ATP regulation of the enzyme may affect multiple intracellular pathways. In this study, ATP was identified as a potential allosteric regulator of NAT1, inhibiting the enzyme within its physiological concentration. Kinetic studies using the wild-type protein showed a non-competitive interaction with the acetyl acceptor (PABA) and a competitive interaction with AcCoA. Experiments with related compounds suggested that the triphosphate of ATP was primarily responsible for inhibition of NAT1 activity.
Using site-directed mutagenesis, the conserved lysine at position 100 has been shown to be important for AcCoA binding to the enzyme [23] . Through an interaction with the 3′-phosphate of AcCoA, Lys 100 stabilized the enzyme-cofactor complex and increased the rate of R.F. Minchin et al. Biochemical Pharmacology 158 (2018) 153-160 productive interactions between the two. In the present study, substitutions of the conserved lysine at position 100 converted ATP from a classical competitive inhibitor of AcCoA into a negative allosteric modulator. This change was due to a loss of the lysine sidechain as opposed to a modification of the charge of the sidechain since both glutamine and arginine substitutions resulted in the same kinetic changes (Fig. 6A ). This result contrasts with the effect of Lys 100 substitutions on NAT1 enzyme activity. A glutamine at this position significantly altered AcCoA binding and reaction rates whereas an arginine did not suggesting charge is important for AcCoA binding [23] . Arginine has often been used as an alternative for lysine to conserve the charge on the sidechain but inhibit possible post-translational modifications. However, these two amino acids are not entirely equivalent. Arginine is capable of forming a greater number of interactions through its guanidinium sidechain, which can alter protein folding and rigidity [27] . The substitution of Lys 100 with glutamine significantly decreased the affinity of AcCoA for NAT1 [23] , but this was not the case with the arginine substitution. By contrast, the affinity of ATP for the enzyme decreased with both substitutions, as demonstrated by the larger IC 50 values. These results suggest that ATP and AcCoA do not interact with the modified protein in the exact same manner.
In silico docking experiments predicted that ATP only interacted within the active site of the enzyme where it was located close to Arg
127
. This amino acid is, in part, responsible for the substrate specificity of NAT1 compared to NAT2. Modelling suggested that ATP might interact with Lys 100 but this amino acid was not essential for the final binding configuration. Nevertheless, since Lys 100 is located near the opening of the active site cleft, it may modulate entry of ATP. A binding configuration, in which the adenine group rather than the phosphates inserted into the binding pocket, was suggested as an alternative by the docking. This, however, appears less consistent with the data showing that guanine or cytosine are well tolerated in place of adenine, while the length of the phosphate chain is critical. ATP inhibition demonstrated a strong positive cooperativity (Hill coefficient > 2) with the modified, but not the wild-type, enzyme. In biological systems that obey Michaelis-Menten type kinetics, there is a near linear relationship between concentration and effect until saturation is approached. By contrast, biological systems that demonstrate positive cooperativity deviate from linearity at low concentrations where the relationship between concentration and effect is more exponential. This cooperativity is applicable to both activators as well as inhibitors of biological reactions. While the molecular mechanisms that underpin cooperativity are diverse [28] , strong positive cooperativity generates a process where activity is less graded and more switch-like in characteristics. Theoretically, this can result from several mechanisms including post-translational modifications [29] . Interestingly, reactions with large Hill coefficients often serve as ultrasensitive switches to amplify or dampen biological effects over a narrow concentration range of the modulator [30] .
The possible functional consequences of Lys 100 modification is depicted in Fig. 7 , which illustrates NAT1 activity as the protein undergoes sequential acetylation and deacetylation in the presence of varying concentrations of ATP. When ATP is low (1-2 mM), unacetylated NAT1 activity is approximately 50% of maximum. Modification of Lys 100 (e.g., acetylation) will switch activity to near maximum since the effect of ATP on the modified enzyme is minimal at these concentrations. Subsequent deacetylation will switch the enzyme back to 50% activity. By contrast, at high ATP concentrations (5 mM), unacetylated NAT1 activity is very low (approximately 10% maximum) and Lys 100 modification has a much less pronounced effect on the enzyme. Thus, changes in Lys 100 acetylation provides a switch for NAT1 activity that is regulated by changes in intracellular ATP. This is the first report of post-translational modification of NAT1 by acetylation. There were attempts to determine whether endogenous NAT1 is acetylated in cells, but these experiments were not successful due to the lack of available anti-NAT1 antibodies that could immunoprecipitate endogenous protein. Consequently, ectopic expression was used to detect modifications. There was no evidence that NAT1 was methylated, ubiquitinated or sumoylated under the conditions used in this study. However, the results to not preclude these as possible posttranslational modifications under different conditions. Polyubiquitination of NAT1 has been demonstrated in cells treated with high concentrations of PABA, or following mutation of various amino acids that destabilize the protein [9] . Mutation of Lys 100 attenuated acetylation but it did not completely eliminate it suggesting that other lysines in NAT1 also undergo acetylation. We are currently investigating which NAT1 lysines may be acetylated and which acetyltransferases/deacetylases regulate this post-translational modification.
The data from the current study support two conclusions. Firstly, ATP is likely to modulate NAT1 activity in vivo since its effects in vitro are seen well within its physiological concentrations. Secondly, posttranslational modification of Lys 100 appears to be central to the changes in NAT1 kinetics by converting the enzyme into an ultrasensitive switch modulated by ATP. Understanding the reason NAT1 is regulated by ATP, and why a cell might want to tightly control that regulation, will provide insight into the endogenous role of the protein. Fig. 7 . NAT1 activity in the presence of different ATP concentrations when NAT1 is un-acetylated (yellow boxes) or acetylated (light green box). Activities were estimated using the kinetic parameters in Tables 1 and 2 . ATP concentrations are shown on the right. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
